David Bates
11Patents
1h-index
11Co-inventors
47Inventor score
Filing activity: Jul 12, 2002 → Sep 19, 2017
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8592563B2 | Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (VEGF) | Chemistry; Metallurgy | 8 | Active |
| US9695160B2 | Piperazine derivatives for treating disorders | Emerging Cross-Sectional Technologies | 1 | Active |
| US10301264B2 | Compounds useful for treating ocular neovasculan | Chemistry; Metallurgy | 1 | Active |
| US9447418B2 | Pro- and anti-angiogenic treatments | Chemistry; Metallurgy | 0 | Active |
| US10696661B2 | Compounds | Chemistry; Metallurgy | 0 | Active |
| US8394930B2 | Growth factor isoform | Physics | 0 | Active |
| US7820178B2 | VEGF isoforms and their use as anti-angiogenic, anti-vasodilatory, anti-permeability and anti-proliferative agents | Physics | 0 | Expired |
| US8530150B2 | Detection of risk of pre-eclampsia | Physics | 0 | Active |
| US9932330B2 | Piperazine derivatives for treating disorders | Emerging Cross-Sectional Technologies | 0 | Active |
| US9796707B2 | Piperazine derivatives for treating disorders | Emerging Cross-Sectional Technologies | 0 | Active |
| US8933211B2 | Growth factor isoform | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.